Damian P C Mawer1, David W Eyre2,3, David Griffiths2,3, Warren N Fawley1,4, Jessica S H Martin5, T Phuong Quan2,3, Timothy E A Peto2,3, Derrick W Crook2,3,6, A Sarah Walker2,3, Mark H Wilcox1,5. 1. Department of Microbiology, Leeds Teaching Hospitals NHS Trust, UK. 2. Nuffield Department of Medicine, University of Oxford, UK. 3. National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, UK. 4. Leeds Regional Microbiology Laboratory, Public Health England, UK. 5. Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, UK. 6. Public Health England, Colindale, United Kingdom.
Abstract
Background: The role of symptomatic patients who are toxigenic strain positive (TS+) but fecal toxin negative (FT-) in transmission of Clostridium difficile is currently unknown. Methods: We investigated the contribution of symptomatic TS+/FT- and TS+/FT+ patients in C. difficile transmission in 2 UK regions. From 2-step testing, all glutamate dehydrogenase (GDH)-positive specimens, regardless of fecal toxin result, from Oxford (April 2012 through April 2013) and Leeds (July 2012 through April 2013) microbiology laboratories underwent culture and whole-genome sequencing (WGS), using WGS to identify toxigenic strains. Plausible sources for each TS+/FT+ case, including TS+/FT- and TS+/FT+ patients, were determined using WGS, with and without hospital admission data. Results: A total of 1447 of 12772 (11%) fecal samples were GDH positive, 866 of 1447 (60%) contained toxigenic C. difficile, and fecal toxin was detected in 511 of 866 (59%), representing 235 Leeds and 191 Oxford TS+/FT+ cases. TS+/FT+ cases were 3 times more likely to be plausibly acquired from a previous TS+/FT+ case than a TS+/FT- patient. Fifty-one of 265 (19%) TS+/FT+ cases diagnosed >3 months into the study were genetically related (≤2 single-nucleotide polymorphisms) to ≥1 previous TS+/FT+ case or TS+/FT- patient: 27 (10%) to only TS+/FT+ cases, 9 (3%) to only TS+/FT- patients, and 15 (6%) to both. Only 10 of 265 (4%) were genetically related to a previous TS+/FT+ or TS+/FT- patient and shared the same ward simultaneously or within 28 days. Conclusions: Symptomatic TS+/FT- patients were a source of C. difficile transmission, although they accounted for less onward transmission than TS+/FT+ cases. Although transmission from symptomatic patients with either fecal toxin status accounted for a low overall proportion of new cases, both groups should be infection control targets.
Background: The role of symptomatic patients who are toxigenic strain positive (TS+) but fecal toxin negative (FT-) in transmission of Clostridium difficile is currently unknown. Methods: We investigated the contribution of symptomatic TS+/FT- and TS+/FT+ patients in C. difficile transmission in 2 UK regions. From 2-step testing, all glutamate dehydrogenase (GDH)-positive specimens, regardless of fecal toxin result, from Oxford (April 2012 through April 2013) and Leeds (July 2012 through April 2013) microbiology laboratories underwent culture and whole-genome sequencing (WGS), using WGS to identify toxigenic strains. Plausible sources for each TS+/FT+ case, including TS+/FT- and TS+/FT+ patients, were determined using WGS, with and without hospital admission data. Results: A total of 1447 of 12772 (11%) fecal samples were GDH positive, 866 of 1447 (60%) contained toxigenic C. difficile, and fecal toxin was detected in 511 of 866 (59%), representing 235 Leeds and 191 Oxford TS+/FT+ cases. TS+/FT+ cases were 3 times more likely to be plausibly acquired from a previous TS+/FT+ case than a TS+/FT- patient. Fifty-one of 265 (19%) TS+/FT+ cases diagnosed >3 months into the study were genetically related (≤2 single-nucleotide polymorphisms) to ≥1 previous TS+/FT+ case or TS+/FT- patient: 27 (10%) to only TS+/FT+ cases, 9 (3%) to only TS+/FT- patients, and 15 (6%) to both. Only 10 of 265 (4%) were genetically related to a previous TS+/FT+ or TS+/FT- patient and shared the same ward simultaneously or within 28 days. Conclusions: Symptomatic TS+/FT- patients were a source of C. difficile transmission, although they accounted for less onward transmission than TS+/FT+ cases. Although transmission from symptomatic patients with either fecal toxin status accounted for a low overall proportion of new cases, both groups should be infection control targets.
Authors: M P M Hensgens; E C Keessen; M M Squire; T V Riley; M G J Koene; E de Boer; L J A Lipman; E J Kuijper Journal: Clin Microbiol Infect Date: 2012-04-27 Impact factor: 8.067
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: Mohammed Sebaihia; Brendan W Wren; Peter Mullany; Neil F Fairweather; Nigel Minton; Richard Stabler; Nicholas R Thomson; Adam P Roberts; Ana M Cerdeño-Tárraga; Hongmei Wang; Matthew T G Holden; Anne Wright; Carol Churcher; Michael A Quail; Stephen Baker; Nathalie Bason; Karen Brooks; Tracey Chillingworth; Ann Cronin; Paul Davis; Linda Dowd; Audrey Fraser; Theresa Feltwell; Zahra Hance; Simon Holroyd; Kay Jagels; Sharon Moule; Karen Mungall; Claire Price; Ester Rabbinowitsch; Sarah Sharp; Mark Simmonds; Kim Stevens; Louise Unwin; Sally Whithead; Bruno Dupuy; Gordon Dougan; Bart Barrell; Julian Parkhill Journal: Nat Genet Date: 2006-06-25 Impact factor: 38.330
Authors: Christopher R Polage; Clare E Gyorke; Michael A Kennedy; Jhansi L Leslie; David L Chin; Susan Wang; Hien H Nguyen; Bin Huang; Yi-Wei Tang; Lenora W Lee; Kyoungmi Kim; Sandra Taylor; Patrick S Romano; Edward A Panacek; Parker B Goodell; Jay V Solnick; Stuart H Cohen Journal: JAMA Intern Med Date: 2015-11 Impact factor: 21.873
Authors: A Sarah Walker; David W Eyre; David H Wyllie; Kate E Dingle; Rosalind M Harding; Lily O'Connor; David Griffiths; Ali Vaughan; John Finney; Mark H Wilcox; Derrick W Crook; Tim E A Peto Journal: PLoS Med Date: 2012-02-07 Impact factor: 11.069
Authors: David W Eyre; David Griffiths; Alison Vaughan; Tanya Golubchik; Milind Acharya; Lily O'Connor; Derrick W Crook; A Sarah Walker; Tim E A Peto Journal: PLoS One Date: 2013-11-12 Impact factor: 3.240
Authors: Lance R Peterson; Stephen A Young; Thomas E Davis; Zi-Xuam Wang; John Duncan; Christopher Noutsios; Oliver Liesenfeld; John C Osiecki; Michael A Lewinski Journal: J Clin Microbiol Date: 2017-09-27 Impact factor: 5.948
Authors: Marcela Krutova; Ales Briksi; Jan Tkadlec; Miroslav Zajac; Jana Matejkova; Otakar Nyc; Pavel Drevinek Journal: J Clin Microbiol Date: 2019-09-24 Impact factor: 5.948
Authors: Larry K Kociolek; Dale N Gerding; Robyn O Espinosa; Sameer J Patel; Stanford T Shulman; Egon A Ozer Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Mark I Garvey; Craig W Bradley; Martyn A C Wilkinson; Elisabeth Holden Journal: Antimicrob Resist Infect Control Date: 2017-12-19 Impact factor: 4.887
Authors: Laura Behar; David Chadwick; Angela Dunne; Christopher I Jones; Claire Proctor; Chakravarthi Rajkumar; Paula Sharratt; Philip Stanley; Angela Whiley; Mark Wilks; Martin J Llewelyn Journal: J Infect Date: 2017-04-21 Impact factor: 6.072